Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
58 hedge funds and large institutions have $147M invested in Syros Pharmaceuticals, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 16 increasing their positions, 8 reducing their positions, and 5 closing their positions.
7,500% more call options, than puts
Call options by funds: $684K | Put options by funds: $9K
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
206% more capital invested
Capital invested by funds: $47.9M → $147M (+$98.9M)
100% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 8
21% more funds holding
Funds holding: 48 → 58 (+10)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
+$5.11M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.04M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.62M |
| 4 |
AG
Artal Group
Luxembourg
|
+$3.53M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$3.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$175K |
| 2 |
SC
Shay Capital
New York
|
-$93.9K |
| 3 |
DMKJ
David M. Knott Jr
|
-$89.2K |
| 4 |
Corient Private Wealth
Miami,
Florida
|
-$50.2K |
| 5 |
LPL Financial
San Diego,
California
|
-$29.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
RhumbLine Advisers
Boston,
Massachusetts
| $5.13K | – | – | – |
|
52
JP Morgan Chase
New York
| $4.28K | -$1.81K | -528 | -49% |
|
53
Wells Fargo
San Francisco,
California
| $4.2K | -$346 | -101 | -16% |
|
|
IA
54
IFP Advisors
Tampa,
Florida
| $3.41K | – | – | – |
|
55
Fifth Third Bancorp
Cincinnati,
Ohio
| $1K | – | – | – |
|
|
SIS
56
Sound Income Strategies
Ft Lauderdale,
Florida
| $592 | – | – | – |
|
|
PA
57
PSI Advisors
Tampa,
Florida
| $101 | +$45 | +13 | New |
|
|
SPIA
58
Steward Partners Investment Advisory
New York
| $62 | +$27 | +8 | New |
|
|
SC
59
Shay Capital
New York
| – | -$93.9K | -23,776 | Closed |
|
60
UBS Group
Zurich,
Switzerland
| – | -$4.32K | -1,093 | Closed |
|
61
Fidelity Investments
Boston,
Massachusetts
| – | -$1.37K | -346 | Closed |
|
|
FFA
62
Farther Finance Advisors
San Francisco,
California
| – | -$79 | -20 | Closed |
|
SYRS Hedge Fund Activity: Q4 2023 in Review
58 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q4 2023, worth a combined $147M — up 206% from $47.9M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new SYRS positions and 5 closed out — a net gain of 11 holders — while 16 added to existing stakes and 8 trimmed.
The largest buyer was Blue Owl Capital Holdings, opening a new position worth an estimated $5.11M. The largest seller was DAFNA Capital Management, cutting an estimated $175K.
- 58 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q4 2023, up from 48 in Q3 2023.
- Funds reported $147M of Syros Pharmaceuticals, Inc. Common Stock stock for Q4 2023, up 206% quarter-over-quarter.
- 16 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q4 2023 and 5 closed out, a net change of +11 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q4 2023 was Blue Owl Capital Holdings, an estimated $5.11M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q4 2023 was DAFNA Capital Management, an estimated $175K sold.
Based on aggregated 13F filings for Q4 2023.